• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    SC 13G/A 1 glto13Agv3.htm 13G / A Template
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549


    SCHEDULE 13G/A


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (AMENDMENT N0. 1)


    Galecto, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    36322Q107

    (CUSIP Number)


    August 29, 2024

    (Date of Event Which Requires Filing of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         |_| Rule 13d-1(b)

         |X| Rule 13d-1(c)

         |_|Rule 13d-1(d)








    CUSIP NO. 045354107

        1 Name Of Reporting Persons
      Erik Otto
       

        2 Check The Appropriate Box If A Member Of A
        Group (See Instructions)
    (a)  |_|
        (b)  |_|
         

        3 SEC Use Only
       

        4 Citizenship Or Place Of Organization
      Canada

        5 Sole Voting Power
    Number of   1

    Shares   6 Shared Voting Power
        0
    Beneficially    

    Owned By   7 Sole Dispositive Power
        1
    Each    

    Reporting   8 Shared Dispositive Power
    Person With   0

        9 Aggregate Amount Beneficially Owned By Each Reporting Person
      1

       10 Check If The Aggregate Amount In Row (9) Excludes Certain Shares
        

       11 Percent Of Class Represented By Amount In Row 9
      0%

       12 Type Of Reporting Person (See Instructions)
      IN





    Item 1 (a). Name of Issuer:  Galecto,Inc.
         
    Item 1 (b). Address of Issuer's Principal Executive Offices:
         
                                         75 State Street
                                         Suite 100
                                         Boston, MA  02109
                        
         
    Item 2 (a). Name of Person Filing:  Erik Otto
         
    Item 2 (b). Address of Principal Business Office:   144 West Oakview Place, San Antonio, TX 78209  59401
         
    Item 2 (c). Citizenship:  Canada
         
    Item 2 (d). Title of Class of Securities:  Common
         
    Item 2 (e). CUSIP Number:  36322Q107
         

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      (a) |_| Broker or dealer registered under Section 15 of the Act.

      (b) |_| Bank as defined in Section 3(a)(6) of the Act.

      (c) |_| Insurance company as defined in Section 3(a)(19) of the Act.

      (d) |_| Investment company registered under Section 8 of the Investment Company Act.

      (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1) (ii)(E);

      (f) |_| An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

      (g) |_| A parent holding company, in accordance with Rule 13d-1(b)(ii)(G);

      (h) |_| A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

      (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

      (j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

    Item 4. Ownership.
         

      (a) Amount beneficially owned:  0
         
      (b) Percent of Class:  0%
         
      (c) Number of shares as to which such person has:

      (i) Sole power to vote or to direct the vote:  1







      (ii) Shared power to vote or to direct the vote:  0
         
      (iii) Sole power to dispose or to direct the disposition of:  1
         
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of Five Percent or Less of a Class:   Yes
         
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:  Not Applicable
         
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:  Not Applicable
         
    Item 8. Identification and Classification of Members of the Group:  Not Applicable
         
    Item 9. Notice of Dissolution of Group.
         
    Item 10. Certification.

            By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.

    SIGNATURE

            After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:   August 29, 2024

    /s/ Erik Otto                      
    Signature
    Get the next $GLTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Financials

    Live finance-specific insights

    See more
    • Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

      Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

      10/7/24 8:45:46 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

      Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

      11/8/22 6:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

      Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

      10/31/22 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Winslow Garrett converted options into 1,320 shares and sold $2,638 worth of shares (471 units at $5.60), increasing direct ownership by 531% to 1,009 units (SEC Form 4)

      4 - Galecto, Inc. (0001800315) (Issuer)

      1/7/25 4:00:07 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Schambye Hans T. converted options into 2,640 shares and sold $7,510 worth of shares (1,341 units at $5.60), increasing direct ownership by 62% to 3,397 units (SEC Form 4)

      4 - Galecto, Inc. (0001800315) (Issuer)

      1/7/25 4:00:03 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Interim CFO Firmani Lori converted options into 726 shares and sold $1,469 worth of shares (261 units at $5.63) (SEC Form 4)

      4 - Galecto, Inc. (0001800315) (Issuer)

      1/7/25 4:00:06 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GLTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Galecto Inc.

      SC 13G/A - Galecto, Inc. (0001800315) (Subject)

      11/7/24 3:07:49 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galecto Inc.

      SC 13G - Galecto, Inc. (0001800315) (Subject)

      11/7/24 2:55:56 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Galecto Inc.

      SC 13G/A - Galecto, Inc. (0001800315) (Subject)

      8/29/24 5:59:56 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

      BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

      10/15/24 8:30:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

      BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto. Dr. Oestreich joins Galecto from Mnemo Therapeutics where she served as Vice President of Operations and Head of Alliance Management. She previously held the role of Executive Vice President at Evotec, a biotech company focusing on developing and delivering new medicines, and has previously served in a number of senior roles

      1/5/22 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Appoints Garrett Winslow as General Counsel

      BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Garrett Winslow has joined the Company as Senior Vice President, General Counsel. In this role, Mr. Winslow will lead the Company's legal, compliance and enterprise risk management functions, reporting to Hans Schambye, CEO. Garrett Winslow brings to Galecto over 15 years of experience working with public companies in the life sciences industry. Prior to joining Galecto, he served as the General Counsel of Spring Bank Pharmaceuticals.  He was also a partner in the Corporate and Securitie

      5/11/21 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse reiterated coverage on Galecto with a new price target

      Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously

      8/6/21 10:59:40 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on Galecto with a new price target

      Credit Suisse resumed coverage of Galecto with a rating of Outperform and set a new price target of $12.00

      4/26/21 8:53:50 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse Group reiterated coverage on Galecto with a new price target

      Credit Suisse Group reiterated coverage of Galecto with a rating of Outperform and set a new price target of $12.00 from $29.00 previously

      3/16/21 8:17:33 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Galecto Inc.

      DEFA14A - Galecto, Inc. (0001800315) (Filer)

      4/30/25 4:00:04 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Galecto Inc.

      DEF 14A - Galecto, Inc. (0001800315) (Filer)

      4/30/25 7:00:10 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Galecto Inc.

      PRE 14A - Galecto, Inc. (0001800315) (Filer)

      4/17/25 4:00:10 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galecto Reports Full-Year 2024 Financial Results

      Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge MedicinesGB3226 on track for IND submission in Q1 2026Phase 2 investigator-initiated trial (IIT) of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic melanoma and head and neck squamous cell carcinoma continues to enroll patients BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial r

      3/19/25 4:45:00 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto to Participate in Upcoming Investor Conferences

      BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM   Location: Virtual A live webcast of the presentation will be available via the Upcoming Events section of the Company's investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay wi

      2/6/25 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Reports Third Quarter 2024 Financial Results

      -  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines -  Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today reported financial results for the third quarter ended September 30, 2024. "The third quarter was a pivotal perio

      11/1/24 8:30:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care